A rise of nearly 1,030% in eleven months is, admittedly, a rather startling figure. Most investors, alas, are driven by herd instinct and will likely mistake such exuberance for a bubble. They are, of course, perfectly entitled to their errors. It was the S&P 500’s best performer in 2025, a fact I mention not to encourage further frenzy, but merely to observe the irony. The masses reward success by overpaying for it.
It’s a peculiar position, really. Holding the keys to the kingdom. A kingdom built on sand, of course, because everything is temporary. But a kingdom nonetheless. They don’t shout about it, these Dutch engineers. They just keep building the machines. The machines that make the machines. It’s a sort of recursive nightmare, if you think about it too hard. Which, naturally, I do.
Bristol Myers Squibb and Intuitive Surgical, two entities not generally associated with the vanguard of technological innovation, are cautiously dipping their toes into these waters. The results, while hardly transformative at this stage, merit a closer inspection, if only to determine whether the accompanying share price adjustments are justified.
The pursuit of artificial intelligence, once the domain of philosophers and science fiction writers, has become a tangible river of capital, carving new channels of prosperity. It is a force that promises to reshape not merely industries, but the very fabric of our lives, offering the illusion of control over chaos. And within this burgeoning landscape, certain companies have emerged, not as mere participants, but as the keepers of the new faith, the architects of this digital renaissance. To invest in them now is not simply to seek financial gain, but to partake in a myth in the making, a prophecy unfolding in lines of code.
By the cessation of trading, the stock’s numerical representation had increased by a margin exceeding twenty-four percent. One wonders, of course, what precisely this signifies, beyond the temporary alignment of digits on a screen.
A hundred times your money. That’s the magic number, isn’t it? A truly enormous ask. It’s like asking a snail to win the Grand Prix. Possible, perhaps, with a very strong tailwind and a distracted field, but terribly unlikely. Let’s not get ahead of ourselves.
Trading volume, a rather vulgar metric, reached 47.5 million shares. A flurry of activity, 52% above the recent, anemic average. The company, a relative newcomer, IPO’d in 2022, and has since experienced a growth exceeding 700%. One begins to wonder if they’ve stumbled upon some forgotten alchemical formula, or simply managed to convince the market that they’re selling not data centers, but dreams.
The stock market, as one observes, has been in a positively exuberant mood of late, all thanks to this artificial intelligence business. However, the average chap on the street isn’t quite feeling the benefit. The labor market is being rather sluggish, inflation is nibbling away at purchasing power, and the prospect of owning a home is, for many, a distant dream. One hears grumbling from retailers and restaurateurs about a distinct lack of spending. A most unfortunate state of affairs, really.
The broader markets were about as exciting as watching paint dry. The S&P 500 (^GSPC +0.03%) inched up 0.03% to 6,915, and the Nasdaq Composite (^IXIC +0.28%) managed a slightly more impressive 0.28% rise to 23,501. Meanwhile, Merck (MRK 0.98%) and BioNTech (BNTX 2.10%) were down slightly. Apparently, even in the world of cutting-edge science, volatility is the only constant. It’s enough to drive a sensible investor to drink… chamomile tea, of course.
But hold your horses. Friday came along, and with it, a bit of a damper. The company offered up a forecast for the next quarter that was, shall we say, less than rosy. Revenue and profits lookin’ to take a tumble, and the stock, naturally, followed suit, fallin’ faster than a politician’s promise. It’s always the way, ain’t it?